Glenmark Pharma Financial Statements

Glenmark Pharma (GLENMARK) reported revenue of ₹133.22B in FY2025 with net income of ₹10.47B. Total assets stood at ₹160.50B and free cash flow was -₹15.77B.

Glenmark Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		109.44B	124.72B	115.83B	126.53B	133.22B
Cost of Rev. Cost of Revenue		-36.99B	-43.85B	-42.58B	-44.13B	-43.53B
Gross Profit		72.45B	80.86B	73.26B	82.40B	89.68B
SGA Sales, General & Admin		-51.61B	-55.99B	-26.01B	-62.04B	-30.22B
Op. Income Operating Income		16.41B	20.00B	10.66B	14.53B	18.65B
PBT Profit Before Tax		13.82B	14.41B	2.40B	364.95M	13.99B
Net Income		9.70B	9.94B	2.97B	-14.34B	10.47B
Dil. Shares Diluted Shares		282.17M	282.17M	282.17M	282.18M	282.21M
Diluted EPS		34.38	33.37	10.53	-53.22	37.11

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Glenmark Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Glenmark Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		73.60B	82.82B	107.26B	75.28B	92.95B
Non-curr. assets Total non-current assets		82.44B	88.01B	86.46B	67.81B	67.54B
Total assets		156.04B	170.83B	193.72B	143.09B	160.50B
Curr. liabilities Total current liabilities		42.01B	46.89B	51.05B	58.19B	59.67B
Non-curr. liab. Total non-current liabilities		43.38B	29.56B	44.27B	6.92B	12.33B
Total liabilities		85.39B	76.45B	95.32B	65.11B	72.00B
Total equity		70.64B	94.38B	98.39B	78.48B	88.49B
Total liab. & eq. Total liabilities & equity		156.04B	170.83B	193.72B	143.59B	160.50B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Glenmark Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Glenmark Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		13.82B	14.41B	8.68B	5.69B	13.99B
Operating CF Cash flow Operating Activities		11.31B	11.09B	6.25B	-2.65B	-8.28B
Capex Investments in PPE		-7.75B	-7.90B	-6.08B	-8.98B	-7.50B
Investing CF Cash flow Investing Activities		-6.75B	-3.33B	-5.28B	45.61B	20.94M
Dividend Paid		-704.47M	-926.95M	-1.37B	-1.18B	-704.42M
Financing CF Cash flow Financing Activities		-4.42B	-5.20B	-774.56M	-39.06B	7.87B
Cash (start) Cash at beginning of period		11.10B	11.38B	14.11B	14.43B	16.58B
Cash (end) Cash at end of period		11.38B	14.11B	14.43B	16.58B	16.76B
FCF Free Cash Flow		3.56B	3.19B	176.29M	-11.64B	-15.77B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Glenmark Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025